全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Biography

Dr. Hua Xie is a professor and principal investigator of Shanghai Institute of Materia Medica (SIMM) and Zhongshan Institute for Drug Discovery (ZIDD). Her research mainly focuses on discovery and development of innovative anticancer drugs. She has played a leading role in the development of three novel drug candidates. ASK120067 that targets EGFR T790M mutations for non-small cell lung cancer is set out to new drug application process in China. She has published more than 60 research articles in peer-review journals including prestigious international journals in the fields of tumor pharmacology and oncology, such as Molecular Cancer and Cancer Research.

Education

1.2001.09-2004.07 Zhengzhou University, Ph.D. in Medicine

2.1996.09-1999.07 Zhengzhou University, M.A. in Pharmacology

3.1989.09-1994.07 Zhengzhou University, B.S. in Clinical Medicine

Work Experience

1.2020.03-now  Shanghai Institute of Materia Medica and Zhongshan Institute for Drug Discovery, Principal Investigator,Professor

2.2013.09-2020.01 Shanghai Institute of Materia Medica, Professor

3.2011.01-2012.06 Hormel Institute, University of Minnesota, Postdoctoral fellow

4.2004.08-2013.08 Shanghai Institute of Materia Medica, Postdoctoral fellow, Assistant Professor, Associate Professor

5.1994.08-2004.07 Zhengzhou University，Assistant, Lecturer

Research Directions

1.Discovery and development of molecularly targeted anticancer drugs;

2.Exploring molecular mechanisms and biomarkers of anticancer drugs;

3.Discovery of molecular basis of drug resistance.

Achievements

1.Three anticancer drug candidates entered into clinical trials.

2.Hold 29 domestic or international patents.

3.Pulished more than 60 research articles in SCI-sited journals.

Publications

Selected Publications：

1. T Zhang^#, R Qu^#, SP Chan^#, MZ Lai, LJ Tong, F Feng, HY Chen, TT Song, PR Song, G Bai, YQ Liu, YN Wang, Y Li, Y Su, YY Shen, YM Sun, Y Chen, MY Geng, K Ding^*, J Ding^*, H Xie^*. Discovery of a novel third- generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19(1):90.

2. S Li^#, T Zhang^#, SJ Zhu^#, C Lei, MZ Lai, LJ Peng, LJ Tong, ZL Pang, XY Lu, J Ding, XM Ren^*, CH Yun^*, H Xie^*, K Ding^*. Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants. ACS Medicinal Chemistry Letters. 2022 Jan 7;13(2):196-202.

3. YQ Liu^#, MZ Lai^#; S Li^#; YN Wang^#, F Feng, T Zhang, LJ Tong, MG Zhang, H Chen, Y Chen, PR Song, Y Li, G Bai, YNing, HT Tang, Y Fang, Y Chen, XY Lu, MY Geng, K Ding^*, K Yu^*, H Xie^*, J Ding^*. LS-106, a novel EGFR inhibitor targeting C797S, exhibits anti-tumor activities both in vitro and in vivo. Cancer Science, 2022 Feb;113(2):709-720.

4. QD Tang^#, T Peng^#, J Hu^#, T Zhang^#, PQ Chen, DX Chen, YJ Wang, LF Chen, LJ Tong, Y Chen, H Xie^*, G Liang^*. Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors. European Journal of Medicinal Chemistry. 2022 Apr 5;233:114249.

5. H Chen^#, MZ Lai^#, T Zhang, YQ Chen, LJ Tong, SJ Zhu, Y Zhou, XM Ren, J Ding, H Xie^*, XY Lu^*, K Ding^*. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. Journal of Medicinal Chemistry. 2022 May 12;65(9):6840-6858.

6. Y Sun^#, HT Tang^#, XY Wang^#, F Feng, TT Fan, DM Zhao, B Xiong^*, H Xie^*, TC Liu^*. Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022 Dec;37(1):1411-1425.